Gene · 10683
Papers2,335
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 2,335
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Expanding the immunotherapy universe in extensive-stage small cell lung cancer: from chemoimmunotherapy backbone to next-wave combinations. | Front Immunol | 2025 | 41415276 | PubTator, text mining | PubMed |
| Tarlatamab for small-cell lung cancer. | Expert Opin Biol Ther | 2025 | 41401368 | PubTator, text mining | PubMed |
| Multi-center Assessment of DLL3 Expression by Immunohistochemistry in Medullary Thyroid Carcinoma. | Endocr Pathol | 2025 | 41345358 | PubTator, text mining | PubMed |
| Early Pseudoprogression Mimicking Pneumonitis After Tarlatamab Therapy: A Case Suggestive of Immune Cell-Associated Respiratory Syndrome (ICARS). | Respirol Case Rep | 2025 | 41341983 | PubTator, text mining | PubMed |
| A novel nomogram based on DLL3 and PD-L1 for predicting the prognosis of patients with small cell lung cancer. | BMC Cancer | 2025 | 41331586 | PubTator, text mining | PubMed |
| Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancer. | Mol Cancer | 2025 | 41331472 | PubTator, text mining | PubMed |
| DLL3-targeted immunoPET and radioimmunotherapy ligands. | Am J Nucl Med Mol Imaging | 2025 | 41280558 | PubTator, text mining | PubMed |
| YAP1 defines an emergent, plastic population of relapsed small cell lung cancer. | bioRxiv | 2025 | 41279637 | PubTator, text mining | PubMed |
| Advancements in extensive-stage small cell lung cancer therapy: from molecular profiling to the advent of precision oncology. | Front Immunol | 2025 | 41268540 | PubTator, text mining | PubMed |
| Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms. | JCO Precis Oncol | 2025 | 41264896 | PubTator, text mining | PubMed |
| DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy. | JTO Clin Res Rep | 2025 | 41256964 | PubTator, text mining | PubMed |
| Transformation from EGFR-mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming. | Cancer Treat Rev | 2025 | 41205554 | PubTator, text mining | PubMed |
| Phenotypic Landscape of Pulmonary Neuroendocrine Tumors: Subtyped by OTP/ASCL1 Expression Correlated with Histology, Hormones and Outcome. | Endocr Pathol | 2025 | 41196447 | PubTator, text mining | PubMed |
| Bridging Knowledge Gaps in Small Cell Lung Cancer: Data, Challenges and Priorities. | Curr Oncol | 2025 | 41149456 | PubTator, text mining | PubMed |
| Expression of YAP1 delineates distinct subtypes of pulmonary large cell neuroendocrine carcinoma with divergent therapeutic implications. | Transl Lung Cancer Res | 2025 | 41132957 | PubTator, text mining | PubMed |
| Molecular Characteristics and Treatment Implications of TP53 Gain-of-Function Mutations in Non-Small Cell Lung Cancer. | Cancer Med | 2025 | 41128012 | PubTator, text mining | PubMed |
| Safe Treatment of an Extensive-Stage Small-Cell Lung Cancer With Tarlatamab in an Orthotopic Heart Transplantation Patient: A Case Report. | Cureus | 2025 | 41111642 | PubTator, text mining | PubMed |
| Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas. | JCO Precis Oncol | 2025 | 40991884 | PubTator, text mining | PubMed |
| Targeting developmental vulnerabilities in childhood sarcomas. | Cancer Metastasis Rev | 2025 | 40983796 | PubTator, text mining | PubMed |
| Novel therapies targeting delta-like ligand 3 (DLL3) in pulmonary and gastroenteropancreatic neuroendocrine carcinomas. | Cancer Treat Rev | 2025 | 40976218 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10683/papers?page=9